Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flecainide and encainide.

F Furlanello, G Vergara, R Bettini

    European Heart Journal
    |March 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    3D printed monoliths: From powder to an efficient catalyst for antibiotic degradation.

    The Science of the total environment·2023
    Same author

    Brain function and clinical characterization in the Boston adolescent neuroimaging of depression and anxiety study.

    NeuroImage. Clinical·2020
    Same author

    Dynamics of AV coupling during human atrial fibrillation: role of atrial rate.

    American journal of physiology. Heart and circulatory physiology·2015
    Same author

    Treatment of fractures of the tibial plates.

    Archivos. Sociedad de Cirujanos de Hospital, Santiago de Chile·2010
    Same author

    Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial.

    Journal of internal medicine·2010
    Same author

    Traumatic aneurysm of the leg.

    Archivos. Sociedad de Cirujanos de Hospital, Santiago de Chile·2010
    Same journal

    Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

    European heart journal·2026
    Same journal

    The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

    European heart journal·2026
    Same journal

    Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

    European heart journal·2026
    Same journal

    Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis.

    European heart journal·2026
    Same journal

    Myths and misconceptions about high-sensitivity C-reactive protein as a marker of residual inflammatory risk.

    European heart journal·2026
    Same journal

    Vascular Ehlers-Danlos syndrome: should we treat asymptomatic patients?

    European heart journal·2026
    See all related articles

    Flecainide and encainide, potent Class IC antiarrhythmics, effectively treat various tachycardias and arrhythmias. However, they can cause paradoxical arrhythmogenic effects and encainide

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Flecainide and encainide are Class IC antiarrhythmic drugs.
    • These drugs are under clinical evaluation for treating cardiac arrhythmias.

    Purpose of the Study:

    • To evaluate the efficacy and effects of flecainide and encainide.
    • To understand the pharmacokinetic properties of encainide and its metabolites.

    Main Methods:

    • Clinical evaluation of flecainide and encainide.
    • Analysis of drug effects on QRS duration, QT interval, and repolarization.
    • Pharmacokinetic studies of encainide metabolism.

    Main Results:

    • Both drugs prolong QRS duration but not ventricular repolarization.
    • Effective in treating supraventricular and ventricular tachycardias, and atrial fibrillation prophylaxis.

    Related Experiment Videos

  • Encainide exhibits complex pharmacokinetics with active metabolites, leading to inter-individual variability.

    • Conclusions:

    • Flecainide and encainide are powerful antiarrhythmics for specific conditions.
    • Potential for 'paradoxical' arrhythmogenic effects necessitates careful dosing and patient selection.
    • Encainide's variable metabolism requires consideration in clinical treatment.